Amgen Inc.
FORMULATIONS AND DOSAGES FOR ADMINISTERING A COMPOUND THAT INHIBITS MCL1 PROTEIN

Abstract:

Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma. ##STR00001##